Inflammation Research

, Volume 62, Issue 3, pp 325–332 | Cite as

Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers

  • Gregorino Paone
  • Alvaro Leone
  • Sandro Batzella
  • Vittoria Conti
  • Francesco Belli
  • Laura De Marchis
  • Alice Mannocci
  • Giovanni Schmid
  • Claudio Terzano
Original Research Paper


Objectives and design

To date, no sufficiently sensitive and specific single marker has been found to predict the clinical course of sarcoidosis. We designed a cohort study to investigate whether a panel of biomarkers measured in bronchoalveolar lavage (BAL) and peripheral blood could help predict pulmonary function worsening during the clinical course of sarcoidosis.


We analyzed 30 individuals with histologically proven sarcoidosis. At baseline, participants underwent pulmonary function tests (PFTs), fiberoptic bronchoscopy and radiological investigations. BAL and blood cellular profiles were obtained from all individuals and six pro-inflammatory molecules were quantified in BAL and serum. PFTs were performed at follow-up visits over a 2-year period. Using discriminant function analysis, a canonical variable was generated to optimize the accuracy of selected variables in predicting pulmonary function worsening and was validated on a subset of nine consecutive individuals with sarcoidosis.


A combination of 6 markers from BAL was able to predict pulmonary function worsening in 96 % of patients [95 % confidence interval (CI) 84.4–99.81]. We validated the generated formula on a group of nine patients with sarcoidosis, obtaining 77.8 % correct classification (95 % CI 45.3–93.7).


Our results show that a combinational approach could contribute to identifying individuals likely to experience pulmonary function worsening, thus helping to decide the correct therapeutic strategies.


Biomarker Discriminant analysis Disease severity Pulmonary function worsening Sarcoidosis 


  1. 1.
    American Thoracic Society. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736–55.Google Scholar
  2. 2.
    Scadding J. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after 5 years’ observations. Br Med J. 1961;2:1165–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Siltzbach LE, James DG, Neville E, Turiaf J, Battesti JP, Sharma OP, Hosoda Y, Mikami R, Odaka M. Course and prognosis of sarcoidosis around the world. Am J Med. 1974;57:847–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52:525–33.PubMedGoogle Scholar
  5. 5.
    Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Bull Med. 1982;29:27–32.Google Scholar
  6. 6.
    Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32.PubMedGoogle Scholar
  7. 7.
    Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34.PubMedCrossRefGoogle Scholar
  8. 8.
    Reich JM, Johnson RE. Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years. Am J Med. 1985;78:61–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med. 2008;29:445–58.PubMedCrossRefGoogle Scholar
  11. 11.
    Gurrieri C, Bortoli M, Brunetta E, Piazza F, Agostini C. Cytokines, chemokines and other biomolecular markers in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(Suppl 1):S9–14.PubMedGoogle Scholar
  12. 12.
    Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML, British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee, Thoracic Society of Australia, New Zealand Thoracic Society, Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.PubMedGoogle Scholar
  13. 13.
    Spencer LT, Paone G, Krein PM, Rouhani FN, Rivera-Nieves J, Brantly ML. Role of human neutrophil peptides in lung inflammation associated with α-1 antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol. 2004;286:L514–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21:407–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Hunninghake GW, Gilbert S, Pueringer R. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med. 1994;49:893–8.Google Scholar
  16. 16.
    Bargagli E, Mazzi A, Mezzasalma F, Perrone A, Olivieri C, Prasse A, Bianchi N, Pieroni MG, Rottoli P. The analysis of tryptase in serum of sarcoidosis patients. Inflammation. 2009;32:310–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Overall JF, Kleitt JC. Use of canonical variate for classification. In: Applied multivariate analysis. New York: McGraw-Hill; 1978. p. 53–77.Google Scholar
  18. 18.
    Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem IH, Wouters EF. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J. 1999;13:1338–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Tutor-Ureta P, Citores MJ, Castejón R, Mellor-Pita S, Yebra-Bango M, Romero Y, Vargas JA. Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis. Cytom B Clin Cytom. 2006;70:416–22.CrossRefGoogle Scholar
  20. 20.
    Welker L, Jörres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J. 2004;24:1000–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49:1510–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Bargagli E, Bianchi N, Margollicci M, Olivieri C, Luddi A, Coviello G, Grosso S, Rottoli P. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest. 2008;68:479–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Müller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173:781–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Inui N, Matsui T, Suda T, Chida K. Anti-endothelial cell antibodies in patients with sarcoidosis. Chest. 2008;133:955–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, Higaki J. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010;137:1391–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, Bisetti A, Ameglio F. Discriminant analysis on small cell lung cancer and non-small-cell lung cancer by means of NSE and CYFRA-21.1. Eur Respir J. 1995;8:1136–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Ameglio F, Giannarelli D, Cordiali-Fei P, Pietravalle M, Alemanno L, Paone G, Amicosante M, Saltini C, Bisetti A. Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and non-specific serum markers. Am J Clin Pathol. 1994;101:719–25.PubMedGoogle Scholar
  28. 28.
    Iskandrian AS, Heo J, Lemiek J, Ogilby JD. Identification of high risk patients with left main and three-vessel coronary disease using stepwise discriminant analysis of clinical, exercise and tomographic thallium data. Am Heart J. 1993;125:221–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Paone G, De Angelis G, Portalone L, Greco S, Giosué S, Taglienti A, Bisetti A, Ameglio F. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors. Br J Cancer. 1997;75:448–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Drent M, Mulder PG, Wagenaar SS, Hoogsteden HC, van Velzen-Blad H, van den Bosch JM. Differences in BAL fluid variables in interstitial lung diseases evaluated by discriminant analysis. Eur Respir J. 1993;6:803–10.PubMedGoogle Scholar
  31. 31.
    Bertorelli G, Pesci A, Consigli GF, Minisini R, Mori PA, Dall’Aglio PP, Olivieri D. Evaluation of some immunological parameters in interstitial lung disease by discriminant analysis. Respiration. 1988;54(Suppl 1):23–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Beirne P, Pantelidis P, Charles P, Wells AU, Abraham DJ, Denton CP, Welsh KI, Shah PL, du Bois RM, Kelleher P. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J. 2009;34:1376–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Winterbauer RH, Lammert J, Selland M, Wu R, Corley D, Spring-meyer SC. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest. 1993;104:352–61.PubMedCrossRefGoogle Scholar
  34. 34.
    Kieszko R, Krawczyk P, Michnar M, Chocholska S, Milanowski J. The yield of endobronchial biopsy in pulmonary sarcoidosis: connection between spirometric impairment and lymphocyte subpopulations in bronchoalveolar lavage fluid. Respiration. 2004;71:72–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Bargagli E, Madioni C, Prasse A, Fossi A, Filippi R, Bianchi N, Voltolini L, Muller-Quernheim J, Rottoli P. Eosinophilic cationic protein in bronchoalveolar lavage fluid of lung transplant patients. Clin Chem Lab Med. 2008;46:563–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Zagai U, Lundahl J, Klominek J, Venge P, Skold CM. Eosinophil cationic protein stimulates migration of human lung fibroblasts in vitro. Scand J Immunol. 2009;69:381–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Rothkrantz-Kos S, Drent M, Rutgers A, Heeringa P, De Vries J, van Dieijen-Visser MP, Cohen Tervaert JW. Relationship between myeloperoxidase promotor polymorphism and disease severity in sarcoidosis. Eur J Intern Med. 2003;14:296–301.PubMedCrossRefGoogle Scholar
  38. 38.
    Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008;177:330–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Eklund A, van Hage-Hamsten M, Sköld CM, Johansson SG. Elevated levels of tryptase in bronchoalveolar lavage fluid from patients with sarcoidosis. Sarcoidosis. 1993;10:12–7.PubMedGoogle Scholar
  40. 40.
    Paone G, Lucantoni G, Leone A, Graziano P, Gasbarra R, Galluccio G, D’Antoni S, Puglisi G, Girardi E, Schmid G. Human neutrophil peptides stimulate tumor necrosis factor-alpha release by alveolar macrophages from patients with sarcoidosis. Chest. 2009;135:586–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Milman N, Kristensen MS, Bentsen K, Grode G, Frederiksen J. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Sarcoidosis. 1995;12:38–41.PubMedGoogle Scholar
  42. 42.
    Kaarteenaho-Wiik R, Lammi L, Lakari E, Kinnula VL, Risteli J, Ryhänen L, Pääkkö P. Localization of precursor proteins and mRNA of type I and III collagens in usual interstitial pneumonia and sarcoidosis. J Mol Histol. 2005;36:437–46.PubMedCrossRefGoogle Scholar
  43. 43.
    De Smet D, Martens GA, Berghe BV, Meysman M, Heylen O, Gorus FK, De Waele M. Use of likelihood ratios improves interpretation of laboratory testing for pulmonary sarcoidosis. Am J Clin Pathol. 2010;134:939–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Paone G, Di Tanna GL, Leone A, Batzella S, Conti V, Belli F, Galluccio G, Cammarella I, Sebastiani A, Terzano C, Vestri AR. Potential usefulness of a combination of inflammatory markers in identifying patients with sarcoidosis and monitoring respiratory functional worsening. Am J Clin Pathol. 2012;137:497–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2012

Authors and Affiliations

  • Gregorino Paone
    • 1
  • Alvaro Leone
    • 2
  • Sandro Batzella
    • 3
  • Vittoria Conti
    • 4
  • Francesco Belli
    • 3
  • Laura De Marchis
    • 5
  • Alice Mannocci
    • 6
  • Giovanni Schmid
    • 7
  • Claudio Terzano
    • 4
  1. 1.Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences‘Sapienza’ University of Rome, S. Camillo-Forlanini HospitalRomeItaly
  2. 2.Pathology UnitS. Camillo-Forlanini HospitalRomeItaly
  3. 3.Department of Respiratory DiseasesS. Camillo-Forlanini HospitalRomeItaly
  4. 4.Eleonora Lorillard Spencer Cenci Foundation‘Sapienza’ University of RomeRomeItaly
  5. 5.Department of Radiology, Oncology, and Pathology‘Sapienza’ University of RomeRomeItaly
  6. 6.Department of Public Health and Infectious Diseases‘Sapienza’ University of RomeRomeItaly
  7. 7.IRCCS Fondazione Don Carlo Gnocchi-OnlusRomeItaly

Personalised recommendations